期刊文献+

p53、p21^Gip1/WAF1和Gadd45α在乳腺癌中的表达及其意义 被引量:3

Significance and expression of p53, p21clpl/wAn and Gadd45a in breast neoplasm tissues
原文传递
导出
摘要 目的探讨p53、p21^Gip1/WAF1和Gadd45α在乳腺癌中的表达情况及其与临床病理参数和预后的关系。方法采用组织芯片和免疫组化sP法检测133例乳腺癌组织及其癌旁正常组织中p53、p21^Gip1/WAF1和Gadd45α的表达,应用Spearman秩和相关分析两者之间的相关性,应用Kaplan.Meier法和Cox多因素回归模型分析与预后的关系。结果p53、p21^Gip1/WAF1和Gadd45α在乳腺癌组织中的阳性表达率(58.6%和47.4%)高于正常乳腺组织(O%)(P〈0.05);Gadd45et在乳腺癌组织中的阳性表达率(41.4%)低于正常乳腺组织(P〈0.05)。v53与淋巴结转移、临床分期相关,差异均有统计学意义(均P〈0.05),p53、p21^Gip1/WAF1与组织分化程度、局部复发、C—erbB-2状态相关,Gadd45a与组织分化程度、腋窝淋巴结转移、远处转移组、ER/PR阳性状态相关。等级相关分析结果提示p53、p21^Gip1/WAF1表达与p53表达呈正相关,Gadd45a表达与p53表达呈负相关,p53、p21^Gip1/WAF1表达与Gadd45ct表达无相关性。结合随访资料,Kaplan.Meier分析显示p53、p21^Gip1/WAF1、Gadd45a、p53、淋巴结转移、C—erbB-2、TNM分期与预后相关,Cox多因素回归分析提示p53、p21^Gip1/WAF1、C—erbB-2、TNM分期是独立的预后参数,Kaplan-Meier分析提示p53、p21^Gip1/WAF1和p53(+)Gadd45ct(-)与乳腺癌不良预后相关。结论p53、p21^Gip1/WAF1和Gadd45α的表达与乳腺癌的病理参数及预后相关,p53(+)Gadd45ct(-)和p53、p21^Gip1/WAF1(+)可作为独立的预后参数。 Objeαive To explore the expression and significance of p53, p21 Cip1/WAF1 and Gadd45α protein in breast cancer and their correlations with clinicopathologic features and prognosis in breast cancer. Methods The expressions of p53, p21cip1/WAFI and Gadd45a proteins were determined by immunohistochemical staining. The relationship between these three proteins and clinicopathologic features in breast cancer was analyzed by X2 test and Spearman's rank correlation analysis. And the survival analyses were performed with the Kaplan-Meier method and Cox regression. The differences between the curves were examined with the two-tailed Log-rank test. Results In 133 cases of invasive breast cancer, the positive rates of p53, p21cipl/WAFI and Gadd45a protein were 58. 6% , 47.4% and 41.4% respeαively. The expressions of p21clpl/wAFI and p53 in cancer were significantly higher than those in the adjacent mammary gland tissue (P 〈 0. 05) while the expression of Gadd45oL was lower than that in the control mammary gland tissue (P 〈 0.05). The positive rate of p21cIPl/wAn was correlated with the histological stage, local recurrence and positive C-erbB-2. And the positive rate of Gadd45α was correlated with the histological stage, lymph node metastasis, metastasis and positive estrogen receptor/progesterone receptor (ER/PR). The positive rate of p53 was correlated with the lymph node metastasis and TNM stage. Spearman's rank correlation analysis showed that p21Cipl/WAF1 was correlated positively with p53, p53 negatively with Gadd45a while p21cip1/wAF1 had no correlation with Gadd45a. With the follow-up data, Kaplan-Meier analysis showed that p21Cip1/WAF1, Gadd45α, p53, lymph node metastasis, C-erbB-2 positive and TMN stage were associated with prognosis. Furthermore, Cox stepwise hazard analysis shows that p2lcip1/wAvl, Gadd45α, C-erbB-2 and TMN stage were correlated with prognosis of breast cancer. Also the Kaplan-Meier analysis showed that p53 ( + ) Gadd45a ( - ) and p53 ( + ) p21cip1/wAF1 �
出处 《中华医学杂志》 CAS CSCD 北大核心 2012年第34期2389-2393,共5页 National Medical Journal of China
关键词 乳腺肿瘤 p53、p21^Gip1/WAF1 Gadd45α Breast neoplasms p53 p21Clpl/WAVl Gadd45α
  • 相关文献

参考文献15

  • 1赵平,陈万青主编..2010中国肿瘤登记年报[M].北京:军事医学科学出版社,2010:196.
  • 2江泽飞,尉承泽.乳腺癌术前新辅助化疗的若干热点问题[J].中华医学杂志,2009,89(2):73-74. 被引量:19
  • 3唐平,魏兵,杨雯娟,刘裔莎,步宏.乳腺癌预后/预测因子[J].中华病理学杂志,2011,40(2):73-76. 被引量:14
  • 4Xia W, Chen JS, Zhou X, et al localization of p21Cipl/WAFI is Phosphorylation/cytoplasmic associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res, 2004,10 : 3815-3824. 被引量:1
  • 5Lakhani SR, van de Vijver M J, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol, 2002,20:2310-2318. 被引量:1
  • 6Longatto-Filho A, Pinheiro C, Pereira SM, et al. Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre- invasive and invasive lesions of uterine cervix. Gynecol Oncol, 2007, 107: 45-51. 被引量:1
  • 7Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10: 5367-5374. 被引量:1
  • 8乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840. 被引量:192
  • 9Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer,2009,9 : 153-166. 被引量:1
  • 10许少峰,付丽.p53研究的新进展[J].中华病理学杂志,2004,33(6):559-561. 被引量:24

二级参考文献142

  • 1江泽飞,姚开泰,宋三泰.乳腺癌治疗的新循证医学证据和临床实践[J].中华医学杂志,2005,85(43):3025-3027. 被引量:29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312. 被引量:1
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145. 被引量:1
  • 5Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487. 被引量:1
  • 6Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497. 被引量:1
  • 7Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25. 被引量:1
  • 8Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102. 被引量:1
  • 9Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146. 被引量:1
  • 10Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333. 被引量:1

共引文献253

同被引文献4

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部